Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06774222 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

StatusRecruiting
PhasePhase 2
Started2023-09-12
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 14, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Given that a significant proportion of locally advanced gastric cancer patients still die from tumor recurrence after surgery, with long-term therapeutic outcomes stagnating and difficult to further improve, especially for patients with poor tumor regression grade (TRG) after surgery, this study aims to explore a new model of adjuvant therapy by conducting research on the use of Fruquintinib in combination with standard chemotherapy for postoperative treatment of HER2-negative gastric cancer patients with poor TRG, in order to bring greater survival benefits to patients.
Trial Details
NCT Number NCT06774222
Lead Sponsor Henan Cancer Hospital
Conditions Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment 69 participants
Start Date 2023-09-12
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-14